BLUECATBIO NH, INC.

BLUECATBIO NH, INC. specializes in advanced biotechnological research and development, with core capabilities centered on the design, testing, and production of precision diagnostic and therapeutic tools aligned with FDA-regulated standards. Operating under NAICS 334516, the company focuses on the manufacturing of medical devices and in vitro diagnostic systems, emphasizing molecular diagnostics, lab-on-a-chip technologies, and automated sample processing platforms. Their technical expertise includes microfluidics integration, bioanalytical sensor development, and GMP-compliant production workflows, with a demonstrated commitment to quality systems aligned with ISO 13485 principles. The firm differentiates itself through miniaturized, point-of-care device engineering and rapid prototyping of novel biomedical instrumentation tailored for clinical and field-deployable environments. Due to insufficient award data, no specific agency relationships or contract patterns can be identified. The company’s engagement with federal entities remains unverified based on available records. The primary NAICS classification 334516 reflects active involvement in the medical device and diagnostic manufacturing sector, with an industry focus on next-generation diagnostic instrumentation and biocompatible system integration. BLUECATBIO NH, INC. positions itself as a niche developer of compact, high-accuracy diagnostic platforms, serving the evolving needs of clinical laboratories, emergency response units, and defense medical applications. As a small business structured as a 2L entity, BLUECATBIO NH, INC. operates from its base in Lebanon, New Hampshire, with no public certifications on file. The company maintains a focused geographic footprint and is positioned as a specialized contributor to the federal biomedical innovation ecosystem, leveraging agile development practices to support advanced medical technology procurement priorities.